Literature DB >> 22018457

CKD-mineral and bone disorder: core curriculum 2011.

Ranjani N Moorthi1, Sharon M Moe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22018457      PMCID： PMC3983665          DOI： 10.1053/j.ajkd.2011.08.009

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  69 in total

Review 1.  Review article: Bone density in patients with chronic kidney disease stages 4-5.

Authors:  Susan M Ott
Journal:  Nephrology (Carlton)       Date:  2009-06       Impact factor: 2.506

2.  Efficacy of sodium thiosulfate for the treatment for calciphylaxis.

Authors:  L Noureddine; M Landis; N Patel; S M Moe
Journal:  Clin Nephrol       Date:  2011-06       Impact factor: 0.975

3.  Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Authors:  Anna L Zisman; Marta Hristova; L Tammy Ho; Stuart M Sprague
Journal:  Am J Nephrol       Date:  2007-01-11       Impact factor: 3.754

Review 4.  Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.

Authors:  Stuart M Sprague; Daniel Coyne
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 8.237

5.  Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Authors:  Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 8.237

6.  Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Authors:  Jack W Coburn; Hla M Maung; Logan Elangovan; Michael J Germain; Jill S Lindberg; Stuart M Sprague; Mark E Williams; Charles W Bishop
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

7.  The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial.

Authors:  Michael Walsh; Braden J Manns; Scott Klarenbach; Marcello Tonelli; Brenda Hemmelgarn; Bruce Culleton
Journal:  Hemodial Int       Date:  2009-12-22       Impact factor: 1.812

8.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.

Authors:  N A Hamdy; J A Kanis; M N Beneton; C B Brown; J R Juttmann; J G Jordans; S Josse; A Meyrier; R L Lins; I T Fairey
Journal:  BMJ       Date:  1995-02-11

Review 9.  Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification.

Authors:  Willi Jahnen-Dechent; Cora Schäfer; Markus Ketteler; Marc D McKee
Journal:  J Mol Med (Berl)       Date:  2007-12-15       Impact factor: 4.599

10.  Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.

Authors:  Daniela Veit Barreto; Fellype de Carvalho Barreto; Aluízio Barbosa de Carvalho; Lilian Cuppari; Sérgio Antonio Draibe; Maria Aparecida Dalboni; Rosa Maria Affonso Moyses; Kátia Rodrigues Neves; Vanda Jorgetti; Marcio Miname; Raul D Santos; Maria Eugênia Fernandes Canziani
Journal:  Nephron Clin Pract       Date:  2008-11-12
View more
  21 in total

1.  Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease.

Authors:  K Žamboch; K Krejčí; J Škarda; M Tichý; I Überall; P Skýpalová; K Langová; D Stejskal; M Švesták; J Zahálková; V Ščudla; J Zadražil
Journal:  Int Urol Nephrol       Date:  2015-05-01       Impact factor: 2.370

Review 2.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

3.  Clear the Fog around Parathyroid Hormone Assays: What Do iPTH Assays Really Measure?

Authors:  Berthold Hocher; Shufei Zeng
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-05       Impact factor: 8.237

Review 4.  Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Zheng Jiang; Xiaoyan Zhang; Lichuan Yang; Zi Li; Wei Qin
Journal:  Int Urol Nephrol       Date:  2015-11-30       Impact factor: 2.370

Review 5.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

6.  The P2Y2 nucleotide receptor is an inhibitor of vascular calcification.

Authors:  Shaomin Qian; Jenna N Regan; Maxwell T Shelton; April Hoggatt; Khalid S Mohammad; Paul B Herring; Cheikh I Seye
Journal:  Atherosclerosis       Date:  2016-12-15       Impact factor: 5.162

Review 7.  Potential application of klotho in human chronic kidney disease.

Authors:  Javier A Neyra; Ming Chang Hu
Journal:  Bone       Date:  2017-01-20       Impact factor: 4.398

8.  Runx2 Expression in Smooth Muscle Cells Is Required for Arterial Medial Calcification in Mice.

Authors:  Mu-En Lin; Theodore Chen; Elizabeth M Leaf; Mei Y Speer; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2015-05-15       Impact factor: 4.307

9.  Matrix metalloproteinase-1 and -2 as markers of mineral bone disease in chronic kidney disease patients.

Authors:  K Thisiadou; V Liakopoulos; G Dimas; G Koliakos; M Karamouzis
Journal:  Hippokratia       Date:  2017 Jan-Mar       Impact factor: 0.471

Review 10.  Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD.

Authors:  Berthold Hocher; Andreas Pasch
Journal:  Kidney Dis (Basel)       Date:  2017-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.